Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

Jonathan Corren; Pascal Chanez; Mario Castro; Leonardo Fabbri; Vijay N. Joish; Robert E. Evans; Neil M.H. Graham; Vera Mastey; Sara Villeneuve; Gaëlle Bégo-Le Bagousse; Christine Taniou; Puneet Mahajan; Ariel Teper; Gianluca Pirozzi; Laurent Eckert

doi:10.1183/13993003.congress-2016.PA1530

Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

Jonathan Corren, Pascal Chanez, Mario Castro, Leonardo Fabbri, Vijay N. Joish, Robert E. Evans, Neil M.H. Graham, Vera Mastey, Sara Villeneuve, Gaëlle Bégo-Le Bagousse, Christine Taniou, Puneet Mahajan, Ariel Teper, Gianluca Pirozzi, Laurent Eckert

European Respiratory Journal 2016 48: PA1530; DOI: 10.1183/13993003.congress-2016.PA1530

Jonathan Corren

1Medicine, Allergy & Immunology, David Geffen School of Medicine at UCLA, Los Angeles, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pascal Chanez

2U1067 INSERM Respiratory, Aix-Marseille Université, Marseille, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mario Castro

3Department of Medicine, Washington University School of Medicine, Saint Louis, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Leonardo Fabbri

4Department of Medicine, NOCSAE, University of Modena and Reggio Emilia, Modena, Italy

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vijay N. Joish

5Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robert E. Evans

6Clinical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Neil M.H. Graham

7Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vera Mastey

5Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sara Villeneuve

8Stats, Ividata, Levallois-Perret, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gaëlle Bégo-Le Bagousse

9Global Health Economics and Outcomes Research, Sanofi R&D, Chilly Mazarin, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christine Taniou

10BU Pharma and Industry, Experis-IT, Nanterre, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Puneet Mahajan

11Global Health Economics and Outcomes Research, Sanofi R&D, Bridgewater, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ariel Teper

12Research and Development, Sanofi R&D, Bridgewater, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gianluca Pirozzi

12Research and Development, Sanofi R&D, Bridgewater, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Laurent Eckert

13Global Health Economics and Outcomes Research, Sanofi R&D, Chilly Mazarin, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics

Figures

Download figure
Open in new tab
Download powerpoint

Vol 48 Issue suppl 60 Table of Contents

Table of Contents
Index by author

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

Message Subject (Your Name) has sent you a message from European Respiratory Society

Message Body (Your Name) thought you would like to see the European Respiratory Society web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

European Respiratory Journal Sep 2016, 48 (suppl 60) PA1530; DOI: 10.1183/13993003.congress-2016.PA1530

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

European Respiratory Journal Sep 2016, 48 (suppl 60) PA1530; DOI: 10.1183/13993003.congress-2016.PA1530

Share This Article:

Main menu

User menu

Search

Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

Figures

Citation Manager Formats

More in this TOC Section

Related Articles

Contact us

Main menu

User menu

Search

Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

Figures

Citation Manager Formats

Jump To

More in this TOC Section

Related Articles

Contact us